文献速递胸部肿瘤

胸部CT扫描联合X线对比胸部X线用于完全切除的非小细胞肺癌随访(IFCT-0302):一项多中心、开放标签、随机、3期试验

Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2022-08-11

该多中心开放标签随机3期试验纳入1775例完全切除的病理I-IIIA期NSCLC患者,比较CT为基础随访与最小随访(门诊+胸片)。两组总生存无显著差异(中位8.5年 vs 10.3年,调整HR 0.95,95%CI 0.83-1.10,P=0.49)。CT随访组检出更多复发和第二原发肺癌,无严重不良事件。

要点

  • 完全切除的早期NSCLC术后,CT为基础随访较门诊+胸片未延长总生存(调整HR 0.95,95%CI 0.83-1.10)。
  • CT随访组复发检出289例(32.6%),最小随访组246例(27.7%);第二原发肺癌分别为40例(4.5%)和27例(3.0%)。
  • 无与试验程序相关的严重不良事件报告。

核心结论

  • 在术后门诊和胸片随访基础上增加胸部CT扫描未延长NSCLC患者生存,但检出更多早期复发和第二原发肺癌,支持采用CT为基础随访,尤其是在已实施肺癌筛查的国家,并配合其他支持措施。

研究设计与样本

  • 多中心、开放标签、随机3期试验(IFCT-0302),2005年1月3日至2012年11月30日从法国122家医院和三级中心纳入1775例完全切除的病理I-IIIA期NSCLC患者(第6版TNM分期),切除后8周内入组。
  • 患者1:1随机分配至CT为基础随访组(887例:门诊、胸片、胸腹部CT扫描,非腺癌组织学行纤维支气管镜检查)或最小随访组(888例:门诊和胸片),采用计算机生成序列最小化法随机。
  • 随访程序前2年每6个月重复一次,之后每年一次直至5年;主要终点为意向治疗人群的总生存,次要终点包括无病生存。

主要发现

  • 中位总生存:最小随访组8.5年(95%CI 7.4-9.6)vs CT为基础随访组10.3年(95%CI 8.1-未达到),调整HR 0.95(95%CI 0.83-1.10),log-rank P=0.49。
  • 无病生存:最小随访组中位未达到(95%CI 不可估计-不可估计)vs CT为基础随访组4.9年(95%CI 4.3-未达到),调整HR 1.14(95%CI 0.99-1.30),log-rank P=0.063。
  • 复发检出:最小随访组246/888例(27.7%)vs CT为基础随访组289/887例(32.6%)。
  • 第二原发肺癌:最小随访组27/888例(3.0%)vs CT为基础随访组40/887例(4.5%)。
  • 未报告与试验程序相关的严重不良事件。

临床怎么用

  • 原文结论支持采用CT为基础随访,尤其是在已实施肺癌筛查的国家,并配合其他支持措施。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Even after resection of early-stage non-small-cell lung cancer (NSCLC), patients have a high risk of developing recurrence and second primary lung cancer. We aimed to assess efficacy of a follow-up approach including clinic visits, chest x-rays, chest CT scans, and fibre-optic bronchoscopy versus clinical visits and chest x-rays after surgery for resectable NSCLC. METHODS: In this multicentre, open-label, randomised, phase 3 trial (IFCT-0302), patients aged 18 years or older and after complete resection of pathological stage I-IIIA NSCLC according to the sixth edition of the TNM classification were enrolled within 8 weeks of resection from 122 hospitals and tertiary centres in France. Patients were randomly assigned (1:1) to CT-based follow-up (clinic visits, chest x-rays, thoraco-abdominal CT scans, and fibre-optic bronchoscopy for non-adenocarcinoma histology) or minimal follow-up (visits and chest x-rays) after surgery for NSCLC, by means of a computer-generated sequence using the minimisation method. Procedures were repeated every 6 months for the first 2 years and yearly until 5 years. The primary endpoint was overall survival analysed in the intention-to-treat population. Secondary endpoints, also analysed in the intention-to-treat population, included disease-free survival. This trial is registered with ClinicalTrials.gov, NCT00198341, and is active, but not enrolling. FINDINGS: Between Jan 3, 2005, and Nov 30, 2012, 1775 patients were enrolled and randomly assigned to a follow-up group (888 patients to the minimal follow-up group; 887 patients to the CT-based follow-up group). Median overall survival was not significantly different between follow-up groups (8·5 years [95% CI 7·4-9·6] in the minimal follow-up group vs 10·3 years [8·1-not reached] in the CT-based follow-up group; adjusted hazard ratio [HR] 0·95, 95% CI 0·83-1·10; log-rank p=0·49). Disease-free survival was not significantly different between follow-up groups (median not reached [95% CI not estimable-not estimable] in the minimal follow-up group vs 4·9 [4·3-not reached] in the CT-based follow-up group; adjusted HR 1·14, 95% CI 0·99-1·30; log-rank p=0·063). Recurrence was detected in 246 (27·7%) of 888 patients in the minimal follow-up group and in 289 (32·6%) patients of 887 in the CT-based follow-up group. Second primary lung cancer was diagnosed in 27 (3·0%) patients in the minimal follow-up group and 40 patients (4·5%) in the CT-based follow-up group. No serious adverse events related to the trial procedures were reported. INTERPRETATION: The addition of thoracic CT scans during follow-up, which included clinic visits and chest x-rays after surgery, did not result in longer survival among patients with NSCLC. However, it did enable the detection of more cases of early recurrence and second primary lung cancer, which are more amenable to curative-intent treatment, supporting the use of CT-based follow-up, especially in countries where lung cancer screening is already implemented, alongside with other supportive measures. FUNDING: French Health Ministry, French National Cancer Institute, Weisbrem-Benenson Foundation, La Ligue Nationale Contre Le Cancer, and Lilly Oncology. TRANSLATION: For the French translation of the abstract see Supplementary Materials section.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Westeel V, Foucher P, Scherpereel A, et al. Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022. PMID: 35964621. doi:10.1016/S1470-2045(22)00451-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。